143 related articles for article (PubMed ID: 34825282)
21. Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials.
Patel A; Skitzki J
J Surg Oncol; 2022 Jan; 125(1):38-45. PubMed ID: 34897704
[TBL] [Abstract][Full Text] [Related]
22. Melanoma. A multidisciplinary approach for the general surgeon.
Reeves ME; Coit DG
Surg Clin North Am; 2000 Apr; 80(2):581-601. PubMed ID: 10836008
[TBL] [Abstract][Full Text] [Related]
23. Prospective Evaluation of Radar-Localized Reflector-Directed Targeted Axillary Dissection in Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy.
Gallagher KK; Iles K; Kuzmiak C; Louie R; McGuire KP; Ollila DW
J Am Coll Surg; 2022 Apr; 234(4):538-545. PubMed ID: 35290273
[TBL] [Abstract][Full Text] [Related]
24. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C
J Clin Oncol; 2020 Nov; 38(33):3925-3936. PubMed ID: 32946353
[TBL] [Abstract][Full Text] [Related]
25. Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
van der Noordaa MEM; van Duijnhoven FH; Straver ME; Groen EJ; Stokkel M; Loo CE; Elkhuizen PHM; Russell NS; Vrancken Peeters MTFD
Ann Surg Oncol; 2018 Jun; 25(6):1512-1520. PubMed ID: 29511992
[TBL] [Abstract][Full Text] [Related]
26. Surgical approach to patients with low-burden stage III melanoma: Is it time to consider conservative surgery?
Moreno-Ramírez D; Vieira R; Kaufmann R
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):498-500. PubMed ID: 31767498
[No Abstract] [Full Text] [Related]
27. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
28. Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma.
Sarnaik AA; Puleo CA; Zager JS; Sondak VK
Cancer Control; 2009 Jul; 16(3):240-7. PubMed ID: 19556964
[TBL] [Abstract][Full Text] [Related]
29. A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes.
Kounalakis N; Gao D; Gonzalez R; Becker M; Lewis K; Poust J; Pearlman N; Robinson W; McCarter M
Immunotherapy; 2012 Jul; 4(7):679-86. PubMed ID: 22853754
[TBL] [Abstract][Full Text] [Related]
30. Combined inguinal and pelvic lymph node dissection for stage III melanoma.
Hughes TM; Thomas JM
Br J Surg; 1999 Dec; 86(12):1493-8. PubMed ID: 10594495
[TBL] [Abstract][Full Text] [Related]
31. Imaging Updates to Breast Cancer Lymph Node Management.
Chung HL; Le-Petross HT; Leung JWT
Radiographics; 2021; 41(5):1283-1299. PubMed ID: 34469221
[TBL] [Abstract][Full Text] [Related]
32. Is the node of Cloquet the sentinel node for the iliac/obturator node group?
Shen P; Conforti AM; Essner R; Cochran AJ; Turner RR; Morton DL
Cancer J; 2000; 6(2):93-7. PubMed ID: 11069226
[TBL] [Abstract][Full Text] [Related]
33. Frequency of level II and III axillary nodes metastases in patients with positive sentinel lymph nodes in melanoma: a multi-institutional study in Japan.
Tsutsumida A; Takahashi A; Namikawa K; Yamazaki N; Uhara H; Teramoto Y; Takenouchi T; Fukushima S; Yokota K; Uehara J; Matsushita S; Shibayama Y; Hatta N; Masui Y; Uchi H; Fujisawa Y; Ogata D
Int J Clin Oncol; 2016 Aug; 21(4):796-800. PubMed ID: 26759315
[TBL] [Abstract][Full Text] [Related]
34. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
Golshan M; Cirrincione CT; Sikov WM; Carey LA; Berry DA; Overmoyer B; Henry NL; Somlo G; Port E; Burstein HJ; Hudis C; Winer E; Ollila DW;
Breast Cancer Res Treat; 2016 Nov; 160(2):297-304. PubMed ID: 27704226
[TBL] [Abstract][Full Text] [Related]
35. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.
Donker M; Straver ME; Wesseling J; Loo CE; Schot M; Drukker CA; van Tinteren H; Sonke GS; Rutgers EJ; Vrancken Peeters MJ
Ann Surg; 2015 Feb; 261(2):378-82. PubMed ID: 24743607
[TBL] [Abstract][Full Text] [Related]
36. Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial.
Jakub JW; Terando AM; Sarnaik A; Ariyan CE; Faries MB; Zani S; Neuman HB; Wasif N; Farma JM; Averbook BJ; Bilimoria KY; Allred JB; Suman VJ; Grotz TE; Zendejas B; Wayne JD; Tyler DS
J Am Coll Surg; 2016 Mar; 222(3):253-60. PubMed ID: 26711792
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in the care of the patient with malignant melanoma.
Reintgen D; Balch CM; Kirkwood J; Ross M
Ann Surg; 1997 Jan; 225(1):1-14. PubMed ID: 8998115
[TBL] [Abstract][Full Text] [Related]
38. Surgical management of patients with intermediate thickness melanoma: current role of elective lymph node dissection.
Cole DJ; Baron PL
Semin Oncol; 1996 Dec; 23(6):719-24. PubMed ID: 8970593
[TBL] [Abstract][Full Text] [Related]
39. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial.
Schwentner L; Helms G; Nekljudova V; Ataseven B; Bauerfeind I; Ditsch N; Fehm T; Fleige B; Hauschild M; Heil J; Kümmel S; Lebeau A; Schmatloch S; Schrenk P; Staebler A; Loibl S; Untch M; Von Minckwitz G; Liedtke C; Kühn T
Breast; 2017 Feb; 31():202-207. PubMed ID: 27889596
[TBL] [Abstract][Full Text] [Related]
40. Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.
van Loevezijn AA; van der Noordaa MEM; Stokkel MPM; van Werkhoven ED; Groen EJ; Loo CE; Elkhuizen PHM; Sonke GS; Russell NS; van Duijnhoven FH; Vrancken Peeters MTFD
Breast Cancer Res Treat; 2022 May; 193(1):37-48. PubMed ID: 35239072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
